Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Fecal microbiota transplantation (FMT) is a promising therapy for inducing and maintaining remission in patients with ulcerative colitis (UC). However, FMT has not been approved for UC treatment in Korea. Our study aimed to investigate patient perceptions of FMT under the national medical policy. Methods: This was a prospective, multicenter study. Patients with UC ≥ 19 years of age were included. Patients were surveyed using 22 questions on FMT. Changes in perceptions of FMT before and after education were also compared. Results: A total of 210 patients with UC were enrolled. We found that 51.4% of the patients were unaware that FMT was an alternative treatment option for UC. After reading the educational materials on FMT, more patients were willing to undergo this procedure (27.1% vs. 46.7%; p < 0.001). The preferred fecal donor was the one recommended by a physician (41.0%), and the preferred transplantation method was the oral capsule (30.4%). A large proportion of patients (50.0%) reported that the national medical policy influenced their choice of FMT treatment. When patients felt severe disease activity, their willingness to undergo FMT increased (92.3% vs. 43.1%; p = 0.001). Conclusions: Education can increase preference for FMT in patients with UC. When patients have severe disease symptoms or their quality of life decreases their willingness to undergo FMT increases. Moreover, national medical policies may influence patient choices regarding FMT.
Abstract
Background/Aims: Fecal microbiota transplantation (FMT) is a promising therapy for inducing and maintaining remission in patients with ulcerative colitis (UC). However, FMT has not been approved for UC treatment in Korea. Our study aimed to investigate patient perceptions of FMT under the national medical policy. Methods: This was a prospective, multicenter study. Patients with UC ≥ 19 years of age were included. Patients were surveyed using 22 questions on FMT. Changes in perceptions of FMT before and after education were also compared. Results: A total of 210 patients with UC were enrolled. We found that 51.4% of the patients were unaware that FMT was an alternative treatment option for UC. After reading the educational materials on FMT, more patients were willing to undergo this procedure (27.1% vs. 46.7%; p < 0.001). The preferred fecal donor was the one recommended by a physician (41.0%), and the preferred transplantation method was the oral capsule (30.4%). A large proportion of patients (50.0%) reported that the national medical policy influenced their choice of FMT treatment. When patients felt severe disease activity, their willingness to undergo FMT increased (92.3% vs. 43.1%; p = 0.001). Conclusions: Education can increase preference for FMT in patients with UC. When patients have severe disease symptoms or their quality of life decreases their willingness to undergo FMT increases. Moreover, national medical policies may influence patient choices regarding FMT.
참고문헌 (23)
- Murray A, "Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, 8, pp.CD000544~ (2020)
- Mantzaris GJ, "Thiopurines and methotrexate use in IBD patients in a biologic era", Curr Treat Options Gastroenterol, 15, pp.84~104 (2017)
- Jun YK, "Infectious complications in patients with inflammatory bowel disease in Asia : the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting", Intest Res, 21, pp.353~362 (2023)
- Magro F, "Inflammatory bowel disease-non-biological treatment", Pharmacol Res, 160, pp.105075~ (2020)
- Al-Bawardy B, "Novel and emerging therapies for inflammatory bowel disease", Front Pharmacol, 12, pp.651415~ (2021)
- Tariq R, "Durability and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with moderate to severe inflammatory bowel disease", Intest Res, 22, pp.208~212 (2024)
- Arora U, "The practice of fecal microbiota transplantation in inflammatory bowel disease", Intest Res, 22, pp.44~64 (2024)
- Moayyedi P, "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial", Gastroenterology, 149, pp.102~109 (2015)
- Rossen NG, "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis", Gastroenterology, 149, pp.110~118 (2015)
- Paramsothy S, "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis : a randomised placebo-controlled trial", Lancet, 389, pp.1218~1228 (2017)
- Costello SP, "Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis : a randomized clinical trial", JAMA, 321, pp.156~164 (2019)
- Paramsothy S, "Faecal microbiota transplantation for inflammatory bowel disease : a systematic review and meta-analysis", J Crohns Colitis, 11, pp.1180~1199 (2017)
- Sood A, "Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis : a real world intention-to-treat analysis", Intest Res, 17, pp.78~86 (2019)
- Zeitz J, "Patients’ views on fecal microbiota transplantation : an acceptable therapeutic option in inflammatory bowel disease?", Eur J Gastroenterol Hepatol, 29, pp.322~330 (2017)
- Roggenbrod S, "Patient perception and approval of fecal microbiota transplantation (FMT) as an alternative treatment option for ulcerative colitis", Z Gastroenterol, 57, pp.296~303 (2019)
- Gundling F, "Patient perception and approval of faecal microbiota transplantation(FMT)as an alternative treatment option for obesity", Obes Sci Pract, 5, pp.68~74 (2018)
- Kahn SA, "Patient perceptions of fecal microbiota transplantation for ulcerative colitis", Inflamm Bowel Dis, 19, pp.1506~1513 (2013)
- Madar PC, "Medical students’perception on fecal microbiota transplantation", BMC Med Educ, 19, pp.368~ (2019)
- Gweon TG, "Recognition and attitudes of Korean physicians toward fecal microbiota transplantation : a survey study", Korean J Intern Med, 38, pp.48~55 (2023)
- Johnson S, "Clinical practice guideline by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA) : 2021 focused update guidelines on management of Clostridioides difficile infection in adults", Clin Infect Dis, 73, pp.e1029~e1044 (2021)
- Bang BW, "Fecal microbiota transplantation for refractory and recurrent clostridium difficile infection : a case series of nine patients", Korean J Gastroenterol, 69, pp.226~231 (2017)
- Yoon H, "Factors related to outcomes of fecal microbiota transplantation in patients with clostridioides difficile infection", Gut Liver, 15, pp.61~69 (2021)
- Peery AF, "AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases", Gastroenterology, 166, pp.409~434 (2024)